<DOC>
	<DOC>NCT02790125</DOC>
	<brief_summary>The primary purpose of this study is to determine if single doses of BMS-986166 are safe and well tolerated in healthy male subjects and female subjects of non-childbearing potential.</brief_summary>
	<brief_title>A Randomized, Double Blind Placebo-Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BMS-986166 in Healthy Subjects</brief_title>
	<detailed_description />
	<criteria>For more information regarding BristolMyers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com Healthy female subjects of nonchildbearing potential or male subjects as determined by medical history, physical examination, vital signs, 12lead electrocardiogram (ECG), and clinical laboratory evaluations Ages 18 to 55 years Female subjects must provide documentation of an acceptable method of surgical sterilization or meet the protocol criteria for menopause Any acute or chronic medical illness judged to be clinically significant by the Investigator and/or Sponsor medical monitor Any acute or chronic bacterial, fungal or viral infection, including tuberculosis, HIV, hepatitis B or hepatitis C, as defined in the protocol History of heart disease, neurological disease, eye disorders or gastrointestinal disorders or surgery (including cholecystectomy) Evidence of organ dysfunction or any clinically significant deviation from normal in physical examination, vital signs, ECGs or clinical laboratory tests Smoking or nicotine use, drug or alcohol abuse within 6 months of starting the study Other protocol defined inclusion/exclusion criteria could apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>